A Phase 3, Double-Blind, Placebo-Controlled Study Evaluating Efficacy And Safety Of Riliprubart In Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Posted Date: Sep 11, 2025
- Investigator: Hani Kushlaf
- Specialties: Neurology, Neuromuscular Disorders
- Type of Study: Drug
The purpose of this Phase 3 study is to evaluate clinical efficacy of riliprubart in patients with CIDP refractory to standard of care therapies, including patients who had insufficient responses. Results from this Phase 3 study will confirm Phase 2 results in a double-blind setting and provide demonstration of clinical efficacy to support registration.
Criteria:
Participant Must Be =18 Years Old At The Time Of Signing The Informed Consent.Participant Must Have Cidp Or Possible Cidp Criteria, Based On Ean/Pns Task Force Cidp Guidelines, Second Revision (2021). Participant Must Be Refractory To Either Immunoglobulin Therapy Or Corticosteroid Therapy. Any Allowed Immunosuppressant Drugs (Azathioprine, Cyclosporine, Or Mycophenolate Mofetil) Have Been Taken For =6 Months At A Stable Dose For =3 Months Prior To Screening.
Keywords:
Cidp
For More Information:
Hannah Fisher
5135584456
fisherhh@ucmail.uc.edu